Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe + atorvastatin versus atorvastatin dose doubling versus rosuvastatin switch in high-risk primary hypercholesterolemia
2009-015247-16Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia comparing Switch to ezetimibe + atorvastatin, Double-dose atorvastatin and Switch to rosuvastatin (3 arms). Primary endpoint: Percent change from baseline in LDL-C. Started Jul 2010; status: completed.
02
Drugs
ezetimibeatorvastatinrosuvastatin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2009-015247-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015247-16.